Efficacy and safety of ribosome-component immune modulator for preventing recurrent respiratory infections in socialized children

Allergy and Asthma Proceedings, 05/09/2012

No statistically significant between–treatment differences were observed for other end points. Both treatments were similarly well tolerated. Six–month treatment with ribosome–component immune modulator (RCIM) effectively prevented the 12–month risk of recurrent respiratory infections (RRIs) in children <5years old and with five or less RRIs in the preceding year.

Print Article Summary Cat 2 CME Report